


X SPANISH DRUG DISCOVERY NETWORK MEETING

22-23 November 2018

Bizkaia Aretoa - **Bilbao** - Spain



WI-FI SSID: EHU-wGuest USER & PASSWORD: SDDN2018

ORGANIZERS

SPANISH

Drug Discovery Network



CICbioGUNE
CENTER FOR COOPERATIVE RESEARCH IN BIOSCIENCES


Universidad
del País Vasco Euskal Herriko
Unibertsitatea

Committees

SCIENTIFIC COMMITTEE

Emilio Diez	Atlas Molecular Pharma
Olga Genilloud	Fundación MEDINA
Jesús Jiménez-Barbero	CIC bioGUNE & UPV/EHU
Gijs Jochems	Promega
Mabel Loza	Univ. Santiago de Compostela USC
María Montoya	CNIC
Oscar Millet	CIC bioGUNE
Jordi Quintana	Univ. Pompeu Fabra UPF
María Jesús Vicent	CIPF

LOCAL ORGANIZING COMMITTEE

Emilio Cocinero	UPV-EHU
Fernando Cossío	UPV-EHU
Emilio Díez	Atlas Molecular Pharma
Jesús Jiménez-Barbero	CIC bioGUNE & UPV/EHU
Oscar Millet	CIC bioGUNE
José Luis Vicario	UPV-EHU

Scientific Programme

SESSION 1

Computational predictive methods for drug discovery

Predictive methods are widely used in many stages throughout the drug discovery process. This session will feature the use of innovative and state-of-the-art computational methods, algorithms and technologies ranging from a better-informed selection of new targets to the acceleration of medicinal chemistry and the prediction of potential liabilities of the new lead molecules.

SESSION 2

Diseased relevant model systems for phenotypic drug discovery

The selection of a suitable model system is critical in the successful advancement of novel therapeutic approaches to disease. The development of models and assays that recapitulate the full complexity of the disease they intend to represent, and the ability to scale them up to screening campaigns remains a big challenge in the drug discovery field. The session will bring together experts in the field presenting innovative models across different disease areas.

SESSION 3

Entrepreneurship and financing drug discovery

The biotechnology industry, including start-up companies originated from Public Research Organisations and Academic Institutions, is responsible today for a considerable proportion of breakthroughs in the treatment of unmet medical needs, having a great impact on Society and the lives of millions of people. In this session, we will have the opportunity to learn from the success of several initiatives with very different origins and technologies, but however all sharing some common features: innovation, enthusiasm, perseverance, and a bit of genuine altruisms.

16:00 - 18:30

SESSION 1

Computational Predictive Methods for Drug Discovery

Humberto González-Díaz
UPV-EHU

Xavier Barril
Univ. Barcelona

Teresa Sardón
Anaxomics

Andrew Leach
EMBL-EBI UK

Sonsoles Martín-Santamaría
CIB-CSIC

18:30 - 19:00

COFFEE BREAK

At Sponsors' Exhibition Area

18:30 - 19:00

POSTER SESSION

Machine learning applied to virtual screening and target identification from biological records stored in public experimental databases.

Sergio Senar

Carbohydrate flexibility modulates the kinetics and thermodynamics of protein binding

Ana Gimeno

NMR studies of the interaction of DC-SIGN with the Blood Group antigens A and B

Pablo Valverde

Molecular recognition of blood group antigens by hgalectin-1

Sara Bertuzzi

Molecular recognition of blood group antigens by hgalectin-1

Sara Bertuzzi

Artificial intelligence in drug development

Nuria E. Campillo

Nmr and modeling studies on the interaction between group b streptococcus type III (GBSIII) antibody and antigenic fragments of the GBSIII capsular polysaccharide

Jon Imanol Quintana

Natural Products as new sources of nuclear translocation inhibitors using High Content Bio-Imaging

Thomas A. Mackenzie

The interaction between Mannose and DC-SIGN. A new binding mode detected by 19F-NMR experiments and MD simulations.

José Daniel Martínez

Molecular target-based design of antiviral strategies against Ebola Virus

Nuria E. Campillo

Herramienta para la evaluación de nanomateriales con componentes alimenticios: las vitaminas.

Ricardo Santana Cabello

PTML Multi-Fold Moving Average Model for Networks of Targets and Allosteric modulators

Javier Llorente

21:30 | DINNER at Bistró Guggenheim

08:30 - 11:00

SESSION 2

Disease Relevant Model Systems for Phenotypic Discovery

Jose Jalife

CNIC-Univ. Michigan

Leo Price

Ocello, Netherlands

Joaquin Castilla

CIC bioGUNE

Robert Vries

Hubrecht Organoid Technology-The Netherlands

11:00 - 11:30

COFFEE BREAK

At Sponsors' Exhibition Area

11:30 - 12:30

POSTER SESSION

Broad Kinome Selectivity and Residence Time Profiling in Living cells using BRET

María Jurado

High Throughput Screening (HTS) to Identify Exosome Biogenesis and Release Inhibitors

Esther Masiá

Zebrafish: Speeding up the new compounds discovery process.

Iranzu Lamberto

Use of 3d spheroids cultures to screen for drugs targeting cancer stem cells

Juan Gumuzio

Advanced partnership PlaXorm for Early Drug Discovery

Olga Balabon

Fragment Libraries from Life Chemicals

Olga Balabon

Epigenetic and PPI Targeted Libraries from Life Chemicals

Olga Balabon

Development of phenotypic in vitro models of pain for early drug discovery

Antón Leandro Martínez Rodríguez

PTML Combinatorial Model for Cancer

Harbil Bediaga

Study of GOINs in Plasmodium Falciparum

Viviana F. Quevedo-Tumaili

Aplicación de un modelo PTMLIF con redes metabólicas en la predicción de la actividad antibacteriana de productos naturales

Deyani Nocado Mena

12:30 - 14:30

SESSION 3

Entrepreneurship and Financing Drug Discovery

Catherine Kettleborough

LifeArc

Teresa Tarragó

iProteos

Patricia Alfonso

Enzymologic

Laureano Simón

Oncomatryx

Andoni Cruz

Biobide

14:30 - 15:30 | COCKTAIL LUNCH

NOTES

22 - 23 November 2018

22 - 23 November 2018

NOTES

ORGANIZERS

SPANISH

Drug Discovery Network 

CICbioGUNE
CENTER FOR COOPERATIVE RESEARCH IN BIOSCIENCES


Universidad
del País Vasco
Euskal Herriko
Unibertsitatea

COLLABORATORS

 **REDEFAR**

 **slas** LABORATORY FOR
LABORATORY AUTOMATION
AND SCREENING
come transform research

SPONSORS

 **Promega**

 **cisbio**
INTERACTION IS EVERYTHING

 **MolPort**

 **LIFE
CHEMICALS**

 **PerkinElmer**
For the Better

HAMAMATSU
PHOTON IS OUR BUSINESS

TECHNICAL SECRETARIAT

 **lidera medical**
gestión de eventos médicos

WI-FI SSID: EHU-wGuest USER & PASSWORD: SDDN2018
WEB www.sddn2108.com
MAIL sddn2108@lideraeventos.com